Failure to control chronic graft dysfunction [e.g. graft @entity455 (GVD)] is the primary cause of immunologic graft failure. This is the first study of @entity618 ( @entity2098 ) for the treatment of GVD in non- @entity1 primate recipients of aortic allografts. Abdominal aortic allografts were exchanged between mixed leukocyte reaction (MLR) -mismatched, blood-group-compatible @entity5434 . Six control recipients were untreated. Individualized treatment with frequent dose adjustments of @entity2098 insured that treatment was close to the maximum tolerated dose (mean 99.2 mg/kg/day). Immune-mediated injury proceeded unhindered until day 45, after which @entity2098 treatment began. Changes in intimal volume (IV) were quantified by intravascular ultrasound (IVUS) and compared to histology on day 105. Serial IVUS measurements of IV (mm(3)) in controls showed progressive GVD. In four out of six animals, @entity2098 was well tolerated, thus enabling optimum treatment; in all these animals, IV was significantly less than in the control animals (p = 0.02). In the two remaining animals, high doses were not tolerated; at day 105, there was no significant difference in IV between them and the controls. We found a significant correlation between the mean @entity2098 tolerated dose and the inhibition of progression of IV (r = -0.88, p = 0.015). When high @entity2098 doses were tolerated, @entity2098 slowed progression of GVD.

Treatment by @entity618 of advanced graft XXXX in non- @entity1 primate recipients of orthotopic aortic allografts.

@entity1 :: ('9606', 'Species') :: ['human'] @entity455 :: ('MESH:D014652', 'Disease') :: ['vascular disease'] @entity5434 :: ('9541', 'Species') :: ['cynomolgus monkeys'] @entity2098 :: ('CHEBI:8764', 'Chemical') :: ['MMF'] @entity618 :: ('MESH:C063008', 'Chemical') :: ['mycophenolate mofetil']
@entity455 :: (MESH:D014652,Disease) :: ['vascular disease']
